Effect of upadacitinib on extraintestinal manifestations in patients with moderately to severely active Crohn's disease

被引：0

作者：

Wright, Emily K. ^{[1
,2
]}

Colombel, Jean-Frederic ^{[3
]}

Hudesman, David ^{[4
]}

Cao, Qian ^{[7
]}

Ghosh, Subrata ^{[8
]}

Reinisch, Walter ^{[9
]}

Lacerda, Ana ^{[5
]}

Dubcenco, Elena ^{[5
]}

Doshi, Chirag ^{[5
]}

Anyanwu, Samuel ^{[5
]}

Feng, Tian ^{[5
]}

Rubin, David ^{[6
]}

机构：

[1] St Vincents Hosp, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY USA

[4] NYU Langone Hlth, Div Gastroenterol, Ctr Inflammatory Bowel Dis, New York, NY USA

[5] AbbVie Inc, N Chicago, IL USA

[6] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[7] Zhejiang Univ, Sir Run Shaw Hosp, Ctr Inflammatory Bowel Dis, Coll Med,Dept Gastroenterol, Hangzhou, Peoples R China

[8] Univ Coll Cork, Coll Med & Hlth, Cork, Ireland

[9] Med Univ Vienna, Clin Dept Gastroenterol & Hepatol, Vienna, Austria

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：159 / 160

页数：2

共 50 条

[21] Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease [J].

Singla, Manish B. ;

Eickhoff, Christa ;

Betteridge, John .

INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) :1637-1642

[22] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease: U-ENDURE Phase 3 Results [J].

Panes, Julian ;

Loftus, Edward, Jr. ;

Lacerda, Ana ;

Peyrin-Biroulet, Laurent ;

D'Haens, Geert ;

Panaccione, Remo ;

Reinisch, Walter ;

Louis, Edouard ;

Chen, Minhu ;

Nakase, Hiroshi ;

Begun, Jakob ;

Boland, Brigid ;

Liu, Jianzhong ;

Dubcenco, Elena ;

Mohamed, Mohamed-Eslam ;

Feng, Tian ;

Colombel, Jean-Frederic .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (12) :S10-S10

[23] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease: U-ENDURE Phase 3 Results [J].

Panes, Julian ;

Loftus, Edward, Jr. ;

Lacerda, Ana ;

Peyrin-Biroulet, Laurent ;

D'Haens, Geert ;

Panaccione, Remo ;

Reinisch, Walter ;

Louis, Edouard ;

Chen, Minhu ;

Nakase, Hiroshi ;

Begun, Jakob ;

Boland, Brigid ;

Liu, Jianzhong ;

Dubcenco, Elena ;

Mohamed, Mohamed-Eslam ;

Feng, Tian ;

Colombel, Jean-Frederic .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 :S10-S10

[24] UPADACITINIB EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE - ANALYSIS OF CELEST STUDY [J].

Mohamed, Mohamed-Eslam F. ;

Kluender, Ben ;

Lacerda, Ana P. ;

Othman, Ahmed A. .

GASTROENTEROLOGY, 2018, 154 (06) :S386-S386

[25] EFFECT OF UPADACITINIB ON LIPID PROFILES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: POOLED ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS [J].

Dubinsky, Marla C. ;

Ha, Christina ;

Armuzzi, Alessandro ;

Irving, Peter M. ;

Fumery, Mathurin ;

Anyanwu, Samuel ;

Lacerda, Ana P. ;

Wang, Tao ;

Suravaram, Smitha ;

Kligys, Kristina ;

Shah, Saajan ;

Duncan, Benjamin ;

Rubin, David T. .

GASTROENTEROLOGY, 2024, 166 (05) :S813-S813

[26] Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn's disease [J].

Reinisch, W. ;

Colombel, J. F. ;

Ma, C. ;

Long, M. ;

Irving, P. M. ;

O'Brien, D. ;

Kligys, K. ;

Song, A. ;

Zhang, Y. ;

D'Haens, G. .

JOURNAL OF CROHNS & COLITIS, 2024, 18 :I1378-I1379

[27] Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn's disease [J].

Gao, X. ;

Cao, Q. ;

Ran, Z. H. ;

Chen, Y. X. ;

Chen, Y. ;

Wen, Z. H. ;

Liu, D. L. ;

Ding, J. ;

Zhong, J. ;

Liu, F. ;

Sha, W. H. ;

An, P. ;

Wang, B. M. ;

Hu, L. X. .

JOURNAL OF CROHNS & COLITIS, 2025, 19 :i1298-i1299

[28] Sustained Remission with Adalimumab Therapy in Japanese Patients with Moderately to Severely Active Crohn's Disease [J].

Hibi, Toshifumi ;

Watanabe, Mamoru ;

Kumar, Ashish ;

Camez, Anne ;

Lomax, Kathleen .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 :S463-S463

[29] MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE [J].

Reguiro, Miguel D. ;

Fischer, Monika ;

Rubin, David T. ;

Shan, Mingyang ;

Deckard, Deanilee ;

Pollack, Paul ;

Hunter, Theresa ;

Chan, Lai Shan ;

Hindryckx, Pieter .

GASTROENTEROLOGY, 2021, 160 (06) :S354-S355

[30] Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension [J].

D'Haens, G. ;

Louis, E. ;

Loftus, E. V. ;

Regueiro, M. ;

Jairath, V. ;

Magro, F. ;

Nakase, H. ;

Dubcenco, E. ;

Lacerda, A. P. ;

Feng, T. ;

Duncan, B. ;

Wang, T. ;

Ford, S. ;

Anyanwu, S. I. ;

Blumenstein, I. .

JOURNAL OF CROHNS & COLITIS, 2024, 18 :I17-I18

← 1 2 3 4 5 →